ライフサイエンスコーパス: colposcopy

1 elial lesion (LSIL; benchmark indication for colposcopy).

2 ne coverage: 96.9 [95% CI, 96.8-97.0] excess colposcopies).

3 reductions in cervical cancer screening and colposcopy.

4 tected by Pap test to determine the need for colposcopy.

5 ere followed semiannually with Pap tests and colposcopy.

6 ested positive on any test were referred for colposcopy.

7 se with LSIL), possibly warranting immediate colposcopy.

8 by Luminex assays, and STI clinical signs by colposcopy.

9 nd cervical samples from 72 women undergoing colposcopy.

10 43 cytology specimens from women referred to colposcopy.

11 r) are acquired from 44 patients at clinical colposcopy.

12 nal/cervical epithelial integrity changes on colposcopy.

13 e at 12 months was as effective as immediate colposcopy.

14 tive screening test results was referred for colposcopy.

15 any of the screening tests were referred for colposcopy.

16 r similar proportions (approximately 39%) to colposcopy.

17 included a Pap test, a test for HPV DNA, and colposcopy.

18 ce changes to cervical cancer screenings and colposcopies.

19 centers had higher odds of reporting reduced colposcopies.

20 Of the 2,725 women who underwent enrollment colposcopy, 412 of 472 (87.3%) diagnosed with histologic

21 g fewer cervical cancer screenings (47%) and colposcopies (44% of those who perform the procedure) th

22 veys, including 675 clinicians who performed colposcopy; a subset (n=55) of clinicians completed qual

23 Women were referred for colposcopy according to a protocol.

24 observational study of 690 women referred to colposcopy after abnormal cervical cancer screening resu

25 omen screened with cytology were referred to colposcopy after high grade cytological abnormalities or

26 Reductions in cervical cancer screening and colposcopy among nearly half of clinicians more than 1 y

27 ex HPV16/18-genotyping had fewer unnecessary colposcopies and (if confirmed) could be a potential alt

28 Six underwent colposcopy and 4 required some form of destructive thera

29 udy was conducted to develop a CNN using 320 colposcopy and anoscopy examinations, from 3 device type

30 cal cancer screening results are referred to colposcopy and biopsy for diagnosis of cervical cancer p

31 screening test results and were referred for colposcopy and biopsy.

32 ophytic condylomata acuminata-should undergo colposcopy and biopsy.

33 erence sponsored by the American Society for Colposcopy and Cervical Pathology (ASCCP).

34 actice algorithm from the British Society of Colposcopy and Cervical Pathology and the European Socie

35 can Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Soci

36 bnormal Pap smear by the American Society of Colposcopy and Cervical Pathology.

37 in 2019, a reduction of 55.3%; use rates of colposcopy and cervical procedures decreased 43.2% and 6

38 Use rates of colposcopy and cervical procedures decreased before 2015

39 Colposcopy and diagnostic biopsies were done on women wi

40 more than one of these types) and underwent colposcopy and histological sampling with consensus path

41 to patients diagnosed with high-grade SIL on colposcopy and referral Pap smear.

42 cological examination twice yearly-including colposcopy and tests for human papillomavirus DNA in cer

43 compared in HPV-positive women who underwent colposcopy and were treated by LEEP (n = 195) and those

44 ing with those HPV16/18 positive referred to colposcopy and with dual-stained cytology triage for OHR

45 ing with those HPV16/18 positive referred to colposcopy and with LBC triage for other oncogenic (OHR)

46 r 100 000 women of cytology and HPV testing, colposcopy, and cervical procedures from 1999 to 2019; M

47 rs were examined every 4 months by cytology, colposcopy, and HPV DNA status.

48 ion), semiannual Papanicolaou smears, annual colposcopy, and semiannual colposcopy--were considered.

49 ational Federation of Cervical Pathology and Colposcopy, and the European Society of Pathology.

50 rus (HPV) vaccination on cervical screening, colposcopy, and treatment is incompletely understood.

51 test, tested positive, and were referred for colposcopy; and short term risk of detecting cervical in

52 High-resolution colposcopy/anoscopy is crucial for assessing these regio

53 ed significance or worse (ASC-US+) underwent colposcopy, as did a random 21% of WLWH who were oncHPV[

54 The main limitation of our study was the colposcopy assessment was restricted to individuals who

55 illance by repeat HPV testing, cytology, and colposcopy at 12 months.

56 Women who underwent colposcopy at baseline (n = 2,780) were grouped into 20

57 age who were undergoing clinically indicated colposcopy at two medical centers in North Carolina betw

58 88 patients cancelling appointments and four colposcopy attendees.

59 isk cases can be identified and referred for colposcopy based on a single screening.

60 population of patients (n=988) referred for colposcopy because of a cervical Pap cytology result of

61 Of 133 eligible participants, 41 underwent colposcopy because of a positive result for HPV of the c

62 ee-and-treat protocol, patients referred for colposcopy because of an abnormal Pap smear in cervical-

63 omen with abnormal cytology were referred to colposcopy, biopsy, and treatment as needed.

64 ears with cytologic testing and adherence to colposcopy/biopsy referrals were associated with the hig

65 We showed that colposcopy can be optimised with proper standardisation

66 from a primary care facility and a referral colposcopy clinic in Cape Town, South Africa.

67 triage HPV-positive individuals to immediate colposcopy, clinician sampling, or 12-month recall depen

68 IV Study [WIHS] and 542 from WIHS-affiliated colposcopy clinics).

69 women with SLE, 67 with abnormal smears from colposcopy clinics, and 15 community subjects with norma

70 y incorporating repeat cytology or immediate colposcopy conducted biennially.

71 Annual colposcopy cost more but provided no additional benefit

72 Colposcopy, currently included in WHO recommendations as

73 nt among HIV-negative MSM, and anoscopy with colposcopy did not increase the detection rate of rectal

74 ulvovaginal swab specimens and collection of colposcopy-directed biopsy specimens.

75 in vivo identification of tumor cells during colposcopy examination, allowing a rapid, noninvasive, a

76 Papanicolaou smear screening, and semiannual colposcopy exceeded $375,000 per QALY saved.

77 nal treatment is preferred, but performing a colposcopy first to confirm the need for excisional trea

78 nd treatment: appointment scheduling, tests, colposcopy, follow-up, treatment of pre-cancerous lesion

79 rm B, women with abnormal cytology underwent colposcopy followed by loop electroexcision procedure (L

80 Non-attendance for colposcopy following cervical screening is higher in dep

81 LETZ for treatment failure and the untreated colposcopy group for preterm birth.

82 included women with untreated CIN (untreated colposcopy group).

83 Compared with the untreated colposcopy group, risk of preterm birth was increased fo

84 visual inspection with acetic acid (VIA) or colposcopy) had close-to-similar effectiveness to HPV sc

85 or a cytological result of ASC-US: immediate colposcopy; human papillomavirus (HPV) triage, which inc

86 cytology at 6 and 12 months and referral for colposcopy if a repeat abnormal result occurs; and recla

87 papillomavirus (HPV) triage, which includes colposcopy if high-risk HPV types are detected; repeat c

88 f additional lesion-directed biopsies during colposcopy increased detection of histologic HSIL, regar

89 Colposcopy is accurate for CIN3+ detection in HPV-positi

90 and a positive HPV test of unknown duration, colposcopy is recommended.

91 cine coverage: 44.1 [95% CI, 40-45.9] excess colposcopies; LBC testing, 80% vaccine coverage: 96.9 [9

92 g rounds, including detection of disease and colposcopies, limits our ability to determine the net be

93 rporate DVI or HPV DNA testing and eliminate colposcopy may offer attractive alternatives to cytology

94 Cytology of a specimen taken at colposcopy (mild dyskaryosis or worse) had 88.9% sensiti

95 Clustering results suggested that colposcopy missed a prevalent precancer in many women wi

96 We aimed to better understand drivers of colposcopy non-attendance and pilot a targeted intervent

97 Compared with referral for colposcopy of all women with ASCUS or higher, signal amp

98 HPV-based algorithm including the immediate colposcopy of HPV-positive women, and then repeat Pap te

99 The approval recommended either colposcopy or a Pap test for patients with specific high

100 nderwent periodic Papanicolaou testing, with colposcopy or biopsy for detected abnormalities.

101 Women with initial normal colposcopy or no high-grade cervical lesions on histolog

102 Whether colposcopy or repeated testing is recommended for hrHPV-

103 gative cytology were randomised to immediate colposcopy or to surveillance by repeat HPV testing, cyt

104 ervical precancer and determine the need for colposcopy or treatment.

105 collected from 135 patients attending either colposcopy or women's clinics in Guayaquil, Ecuador, who

106 rogram of 2 repeat cytology tests, immediate colposcopy, or DNA testing for high-risk types of human

107 mammograms, and 348 000 (no range available) colposcopies over the lifetime.

108 o more likely to be HPV-16 DNA positive than colposcopy patients (P < 0.05).

109 SLE and colposcopy patients were more likely (P < 0.05) to be HP

110 All HPV-16 DNA sequences from 6 SLE and 5 colposcopy patients were the European-type variant.

111 ses in the number of screening Pap tests and colposcopy procedures were consistently observed across

112 All women not selected for colposcopy received their results and exited the study.

113 Colposcopy referral (ages 25-69 years) was 3.5%, increas

114 We aimed to assess colposcopy referral and CIN2+ detection rates for HPV-sc

115 The main outcomes were colposcopy referral and detected CIN2+ rates at baseline

116 sis and the 4-year cumulative proportions of colposcopy referral and treatment by vaccination arm wer

117 Colposcopy referral and treatment were reduced by 21.3%

118 LBC alone, it unacceptably increased excess colposcopy referral by 94%.

119 to histologic outcomes using specimens from colposcopy referral populations at 7 clinical sites in t

120 % positive predictive value (PPV), and a 35% colposcopy referral rate (Colpo).

121 ection rates of CIN2+ without increasing the colposcopy referral rate.

122 t be associated with a transient increase in colposcopy referral rates in the first round of HPV scre

123 Colposcopy referral thresholds need to consider underlyi

124 Colposcopy referral was reduced by 7.9% (P = 0.03) and t

125 U.S. consensus risk threshold for immediate colposcopy referral.

126 ith HPV 16/18 cervical infection detected at colposcopy referral.

127 en with HSIL+ resulted in a 40% reduction in colposcopy referrals but was associated with some loss i

128 IN/HPV16/18 triage would require 4.1 and 2.4 colposcopy referrals to detect one cervical intraepithel

129 ve women with VIA/VILI reduced the number of colposcopy referrals, but with loss in sensitivity for C

130 HR types decreased the number of unnecessary colposcopy referrals.

131 s small-scale study are limited to NHS trust colposcopy service in the northeast of England, thus fur

132 eferred to as patients in this paper) access colposcopy services.

133 Colposcopy showed no abnormal findings with either tampo

134 ing approaches resulted in fewer unnecessary colposcopies than LBC approaches (HPV testing, 80% vacci

135 In women who had colposcopy, the cobas HPV test was more sensitive than l

136 ologic Oncology, the European Federation for Colposcopy, the International Federation of Cervical Pat

137 ansport medium from 1,099 women referred for colposcopy: the Hybrid Capture 2 (Qiagen), Cobas (Roche)

138 We aim to evaluate the performance of colposcopy to detect cervical precancer and cancer for t

139 tailed genital examination and anoscopy with colposcopy to detect herpes lesions.

140 h preterm labor, can be reduced by repeating colposcopy to monitor for precancer and avoiding excisio

141 m the screening and the colposcopy visits, 7 colposcopy triage strategies were defined and evaluated.

142 HPV typing has been recommended for colposcopy triage, but it is not clear which combination

143 HPV-positive women were referred to colposcopy using a standardised protocol, including biop

144 d to cytology and HPV test results until the colposcopy visit was completed.

145 tion test results from the screening and the colposcopy visits, 7 colposcopy triage strategies were d

146 Number of colposcopies was reduced in 2020 compared to previous ye

147 Diagnostic accuracy of colposcopy was assessed by considering a positive test r

148 trually for a broad panel of microorganisms, colposcopy was performed, and diary reports were collect

149 lly for a broad panel of microorganisms, and colposcopy was performed.

150 en the colposcopic impression at the initial colposcopy was positive minor, positive major, or suspec

151 ou smears, annual colposcopy, and semiannual colposcopy--were considered.

152 liquid-based cytology, followed by immediate colposcopy with a reduction of 87% and 91%, respectively

153 Colposcopy with a single biopsy can miss identification

154 PV-positive women were referred for a second colposcopy with biopsy and treatment as needed.

155 ssay and polymerase chain reaction, and anal colposcopy with biopsy of lesions.

156 ve HPV test results), management consists of colposcopy with biopsy or excisional treatment.

157 by the PCR method and 92 underwent screening colposcopy with biopsy prior to knowing the HPV PCR resu

158 Screening programs, such as colposcopy with Papanicolaou testing, have greatly impro